Delivery Order SPE2DB20D3103-SPE2DB25FP8F4
- Not listed
- The Defense Logistics Agency awarded a $33,160.61 delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL), with completion targeted for August 20, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing contract vehicle. The pharmaceutical products will be delivered to Conshohocken, Pennsylvania, where the vendor maintains its corporate office and...
- The Defense Logistics Agency awarded a $5,768.41 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3ml), with performance completion required by July 28, 2025. This is a firm fixed-price delivery order with no set-aside designation, utilizing competitive procurement procedures. The order will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $41,688.44 to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3ml). This firm fixed-price delivery order is set to be completed by August 19, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a competitively awarded, non-set-aside contract for pharmaceutical products supporting federal medical procurement needs. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL) with a ceiling value of $9,153.24. This competitively awarded, firm fixed-price contract represents a single delivery order with an ultimate completion date of August 22, 2025. The order will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,266.60 to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL) with an ultimate completion date of July 24, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award to this pharmaceutical distributor. The place of performance is listed as AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3 mL) with a ceiling value of $1,136.92. This is a firm fixed-price delivery order with an ultimate completion date of July 31, 2025, and represents a non-set-aside competitive award. The order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania location, where the company maintains its corporate headquarters and serves as...
- The Defense Logistics Agency (DLA) awarded a $10,739.93 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Ozempic 0.25–0.5 mg/dose pens (3 mL). This firm fixed-price delivery order is scheduled for completion by July 24, 2025, and will be performed at AmerisourceBergen's location in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation, reflecting the vendor's capability to meet federal procurement requirements through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3ml) with a ceiling value of $3,759.96. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under open competition. The order is scheduled for ultimate completion by September 4, 2025, with performance to be completed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a $14,466.50 delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 0.25-0.5 mg/dose pens (3mL) on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed-price contract, which is not set aside for any specific category, represents a small-value transaction within AmerisourceBergen's broader federal pharmaceutical supply portfolio. The award was competitively awarded and will be performed at the vendor's corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $36,233.87 to AmerisourceBergen Drug Corp for the supply of Ozempic 0.25-0.5 mg/dose pens (3ml) on August 22, 2025, with completion scheduled for August 25, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FP8F4Delivery Order
The Defense Logistics Agency awarded a $46,560.06 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3 ml). The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open competition. Performance will be executed at the vendor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 12, 2025. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion master vehicle running through December 2026 that serves as a comprehensive global pharmaceutical support program. The IDC enables the vendor to supply a broad range of pharmaceuticals and medical commodities to support military healthcare programs worldwide, including specialty medications, brand-name and generic drugs, and vaccines. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for federal medical procurement, has demonstrated consistent capability in fulfilling DLA medical supply requirements across multiple therapeutic domains through competitively awarded contracts ranging from small transactions to substantial orders exceeding $45,000.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $46.6k | 8/11/25 |